LAS VEGAS, Feb. 2, 2021 /PRNewsCentre/ — DelveInsight’s "Peripheral T-Cell Lymphoma (PTCL) Market" report provides an absolute comprehension of the PTCL, historical and forecasted epidemiology and the Peripheral T-Cell Lymphoma market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Peripheral T-Cell Lymphoma market report also proffers an analysis of recent Peripheral T-Cell Lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs.
Some of the essential highlights of the Peripheral T-Cell Lymphoma Market Research Report:
For additional information on Market Impact by Therapies, visit: Peripheral T-cell Lymphoma Treatment Market
Peripheral T-cell Lymphoma (PTCL) is a diverse group of aggressive lymphomas that develop from mature T-cells and natural killer (NK) cells and account for 10–15% of all non-Hodgkin lymphomas worldwide. Most PTCL subtypes are aggressive lymphomas, including PTCL-NOS, AITL, ALCL, enteropathy-type T-cell lymphoma, and extranodal NK cell/T-cell lymphoma. The total Peripheral T-Cell Lymphoma incident population in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan] was 17,057 in 2020.
Download Peripheral T-cell Lymphoma Market Infographic for free
The Peripheral T-cell Lymphoma Market Report provides historical as well as forecasted epidemiological analysis segmented into:
Request for a free sample report for more insights @ PTCL Market Growth
Currently, the PTCL market holds treatment options that are supportive in nature, such as conservative (nonsurgical) and surgical methods. Conservative Peripheral T-Cell Lymphoma treatment further includes physical therapy, behavioural therapies, or pharmacological therapies.
There are only five FDA permitted products for the treatment of PTCL, are Beleodaq (Belinostat, Acrotech Biopharma); Istodax (Romidepsin, Celgene), Folotyn (Pralatrexate, Acrotech Biopharma), Arranon (Nelarabine, GlaxoSmithKline), and Adcetris (Brentuximab vedotin, Seattle Genetics).
There were no approved therapies for first-line treatment in the past years, with no current standard of care for PTCL patients. However, a recent sanction of Adcetris (Brentuximab vedotin) in November 2018 from the US FDA has altered the Peripheral T-cell Lymphoma market landscape. It is now the only FDA-authorised regimen in first-line therapy combined with chemotherapy for adults with formerly untreated systemic ALCL or other CD30-expressing PTCL.
The approved PTCL treatment options in the EU are Adcetris (brentuximab vedotin) and Arranon (nelarabine). Adcetris is an antibody-drug conjugate (ADC) that targets CD30. In Europe, the rejection of the approval for Folotyn (pralatrexate) and Istodax (romidepsin) by The European Medicines Agency (EMA) has affected the Peripheral T-cell Lymphoma market scenario to a large extent. As these products showed a lack of evidence in the clinical benefit, they were withdrawn from the market subsequently. Apart from these, Beleodaq (Belinostat) is not licensed in Europe, although the EMA has granted it orphan designation status.
The approved therapies for the Peripheral T-cell Lymphoma treatment in Japan includes Istodax (romidepsin), Folotyn (pralatrexate), Poteligeo (mogamulizumab), Adcetris (brentuximab vedotin), Mundesine (forodesine hydrochloride), and Arranon (nelarabine). As compared to the US and EU-5, the approved drugs for PTCL and its subtype are more in Japan. However, two approved drugs (Folotyn and Istodax) in Japan are rejected by the EMA due to a lack of evidence in the clinical benefit.
Apart from the available permitted therapies, there are a few off-label therapies and other emerging therapies available for PTCL treatment. Some of the off-label therapies enumerated in the NCCN guidelines for Relapsed PTCL are MabThera (Rituxan), Bortezomib, Bendamustine, Lenalidomide, and Alemtuzumab.
Apart from these approved and off-label therapies, various emerging therapies are being evaluated in clinical trials to treat PTCL and its subtypes. The emerging therapies include Azacitidine, Denileukin diftitox, HBI-8000, COPIKTRA, Tislelizumab, Keytruda, STI-3031/IMC-001, SP-02, Tipifarnib, ALRN-6924, Ruxolitinib, and Romidepsin + Azacitidine and many others.
PTCL Emerging Drugs Along with Key Players
And several others.
Final Comments on Peripheral T-cell Lymphoma Market Growth
Scope of the Peripheral T-cell Lymphoma Market Insight
Request for a Webex demo of the report @ PTCL Market Size
Table of Contents
Executive Summary of Peripheral T-cell Lymphoma (PTCL)
Peripheral T-cell Lymphoma Market Overview at a Glance
PTCL Disease Background and Overview
Case Reports of Peripheral T-cell Lymphoma
Peripheral T-cell Lymphoma Epidemiology and Patient Population
Peripheral T-cell Lymphoma Treatment
Peripheral T-cell Lymphoma Unmet Needs
Peripheral T-cell Lymphoma Marketed Drugs
Beleodaq (Belinostat): Onxeo S.A.
Istodax (Romidepsin): Celgene Corporation
Folotyn (Pralatrexate): Spectrum Pharmaceuticals
Poteligeo (Mogamulizumab): Kyowa Hakko Kirin Co, Ltd.
Adcetris (Brentuximab vedotin): Seattle Genetics
Mundesine (Forodesine Hydrochloride): Mundipharma K. K.
Rituxan (MabThera): Genentech
Arranon (nelarabine): GlaxoSmithKline
Peripheral T-cell Lymphoma Emerging Drugs
Denileukin diftitox: Eisai
SP-02 (Darinaparsin, ZIO-101): Solasia Pharma
Fenretinide (4-HPR): CerRx
Tipifarnib: Kura Oncology
HBI-8000: HUYA Bioscience International/Quintiles, Inc.
COPIKTRA (Duvelisib): Verastem
Genolimzumab (GB226): Genor Biopharma
Azacitidine (CC-486): Celgene Corporation
Lacutamab/IPH4102: Innate Pharma
AFM13: Affimed GmbH
Opdivo (nivolumab) + Cabiralizumab: Bristol-Myers Squibb
Bavencio (avelumab): Pfizer
Keytruda (pembrolizumab): Merck Sharp & Dohme Corp.
STI-3031/IMC-001: Sorrento Therapeutics
ALRN 6924: Aileron Therapeutics
Masitinib: AB Science
Ruxolitinib: Incyte Corporation/Novartis
Aplidin (plitidepsin): PharmaMar
ASTX660: Otsuka Pharmaceutical/Astex Pharmaceuticals
Peripheral T-cell Lymphoma Seven Major Market Analysis
CD30 expression in Peripheral T-cell Lymphoma
Expected Launch Year of PTCL Emerging Therapies
Attribute Analysis Phase III
Attribute Analysis Phase II
United States PTCL Market Outlook
EU-5 PTCL Market Outlook
Germany PTCL Market Size
France PTCL Market Size
Italy PTCL Market Size
Spain PTCL Market Size
United Kingdom PTCL Market Size
Japan PTCL Market Outlook
Peripheral T-cell Lymphoma Market Drivers
Peripheral T-cell Lymphoma Market Barriers
SWOT Analysis of Peripheral T-cell Lymphoma
Reimbursement and Market Access
Browse detailed TOC with charts, figures, tables @ PTCL Market Share
Peripheral T-Cell Lymphomas (PTCL) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Peripheral T-Cell Lymphomas (PTCL) market.
DelveInsight’s Peripheral T-Cell Lymphoma (PTCL) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Peripheral T-Cell Lymphoma.
Peripheral T-Cell Lymphomas (PTCL) – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 " report by DelveInsight offers comprehensive insights on marketed and Phase III products for Peripheral T-Cell Lymphomas (PTCL).
DelveInsight’s ATCL Market report 2030 delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market trends in 7MM.
DelveInsight’s Chronic Bronchitis – Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
DelveInsight’s Mucopolysaccharidosis Market Insights, Epidemiology and Market Forecast – 2030 report provides an in-depth understanding of historical and forecasted epidemiology in 7MM.
DelveInsight’s Knee Osteoarthritis Market Insights, Epidemiology and Market Forecast – 2030 report provides an in-depth understanding of historical and forecasted epidemiology in 7MM.
DelveInsight’ s Deep Vein Thrombosis Market Insights, Epidemiology and Market Forecast – 2030 report provides an in-depth understanding of historical and forecasted epidemiology in 7MM.
DelveInsight’s "Spinal Cord Stimulator Market Insights, Competitive Landscape and Market Forecast-2025" report delivers an in-depth understanding of Spinal Cord Stimulator.
DelveInsight’s, "India Healthcare Outlook Report, 2020," provides comprehensive insights about the healthcare scenario, regulatory policies and reimbursement landscape in India.
DelveInsight’s Meniere’s Disease Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed understanding of historical and forecasted epidemiology.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
SOURCE: DelveInsight Business Research, LLP